The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. Industry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs, […]

Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit! With two exciting LBx approvals in 2020 and investment pouring into the industry, these assays are primed to transform the cancer-care space. To realize these untapped opportunities, it is essential significant sensitivity, selectivity and analytical roadblocks are addressed to prove utility in the clinic. […]

Innovations in technologies and applications of RNA-based medicine RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at […]

Sponsored by: Celvivo Chaired by: Stefan Przyborski, Professor of Cell Technology, Durham University Developing Complex Physiologically Relevant Cell Models in Vitro 3D Cell Culture is gaining momentum in the pharmaceutical industry, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of […]

Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe, Effective & Affordable Advanced Therapies The CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs, breach the solid tumor microenvironment, and deliver affordable CAR and TCR technologies to patients in need. Providing you with the […]

Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need: Say Goodbye to the Worry and Uncertainty of Setting Up and Managing an Expanded Access Program. By bringing together the world’s leading thinkers in Expanded Access Programs, this exclusive platform will clarify the complex issues through end-to-end Expanded Access Program Operationalization. Through […]

The 6th Annual Animal Health Innovation Europe taking place on the 22-23rd February 2021 will showcase the most exciting innovations in animal health and nutrition, connecting those businesses with financial investors and strategic corporate partners, making it the sector’s premier investment forum in Europe. Join us to hear investment pitches, network with C-Suite Executives and learn from […]

The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. With investment at an all-time high, and several indications in late-stage trials gearing up for approval, the meeting will leverage the experience from first to market pioneers, as well as unveiling […]

PURIFY – Chromatography Purification Conclave PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups! The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. The attendees at PURIFY get exposed […]

The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. Building on the success of last year’s […]

Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However, their specificity to only target G12C mutations, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts […]